RNAZ (TransCode Therapeutics) Insider Ownership: 14.86 % (As of Aug. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RNAZ TransCode Therapeutics Inc RNAZ
34 GF Score
Price $3.96
! 1 Warning Sign
View Full Analysis

What is TransCode Therapeutics Insider Ownership?

TransCode Therapeutics RNAZ -7.26% 34 Insider Ownership is 14.86 % as of Aug. 09, 2026. GuruFocus rates RNAZ with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, TransCode Therapeutics's insider ownership is 14.86%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, TransCode Therapeutics's Institutional Ownership is 3.25%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, TransCode Therapeutics's Float Percentage Of Total Shares Outstanding is 99.86%.

TransCode Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for TransCode Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransCode Therapeutics Insider Ownership Chart

TransCode Therapeutics Historical Data

The historical data trend for TransCode Therapeutics can be seen below:

2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2025-04-30
Insider Ownership 52.81 59.74 52.39 47.75 20.10 20.10 20.10 20.10 20.10 14.86
RNAZ
34GF Score
TransCode Therapeutics Inc RNAZ
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransCode Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 14.86 % mean?
TransCode Therapeutics (RNAZ) has a Insider Ownership of 14.86 % as of Aug. 09, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on TransCode Therapeutics and its competitors.
Is TransCode Therapeutics' Insider Ownership too high?
TransCode Therapeutics' current Insider Ownership is 14.86 %. Overall, TransCode Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does TransCode Therapeutics' Insider Ownership compare to BCAB and APVO?
TransCode Therapeutics' Insider Ownership of 14.86 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on TransCode Therapeutics and its competitors. TransCode Therapeutics's current Insider Ownership is 14.86 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransCode Therapeutics stock overvalued right now?
TransCode Therapeutics (RNAZ) has a current Insider Ownership of 14.86 %. The current Insider Ownership is 14.86 %. TransCode Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For TransCode Therapeutics (RNAZ), the current Insider Ownership is 14.86 % as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransCode Therapeutics Business Description

Address 6 Liberty Square, No. 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
34GF Score

Get the complete analysis for RNAZ

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.96
Price